bluebird bio, Inc. (BLUE)

0,9228 +0,0103 (+1,13%) Börsenschluss: 04:00PM EDT

bluebird bio, Inc.

455 Grand Union Boulevard
Somerville, MA 02145
United States
339 499 9300
https://www.bluebirdbio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 323

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Andrew Obenshain	President, CEO & Director	1,04M	N/A	1974
Mr. Thomas J. Klima	Chief Commercial Officer & COO	654,97k	N/A	1972
Mr. Richard A. Colvin M.D., Ph.D.	Chief Medical Officer	696,24k	N/A	1966
Mr. Christopher Krawtschuk CPA	CFO, Principal Accounting Officer & Treasurer	N/A	N/A	1974
Mr. Joseph D. Vittiglio Esq., J.D.	Chief Legal & Business Officer and Secretary	N/A	N/A	1972
Jess Rowlands	Head of Corporate Communications	N/A	N/A	N/A
Ms. Andrea Walton	Chief People Officer	N/A	N/A	N/A
Mr. Kasra Kasraian	Senior Vice President of Technical Development & Operations	N/A	N/A	N/A
Mr. Scott Shoemaker	Senior Vice President of Quality	N/A	N/A	N/A
Ms. Sarah Alspach	Senior Vice President of External Affairs	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

Corporate Governance

bluebird bio, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 5. Die grundlegenden Scores sind Audit: 8, Vorstand: 3, Shareholderrechte: 5, Kompensation: 4.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.